Latest News

STAT Plus: Pharmalittle: Gilead to boost remdesivir supplies in Europe; drug makers announcing $1 billion antibiotic innovation fund



Good morning, everyone, and welcome to another busy day. You made it this far this week, so why not continue, yes? While you ponder the possibilities, we will celebrate a gorgeous morning with some needed cups of stimulation. After the heat and humidity of the past few days, a sparkling sun and coooool breeze are quite welcome. And of course, we are happy to pass along the latest menu of tidbits to get you started on your way. Hope you have a smashing day, and do stay in touch. We accept documents and tips. …

Gilead Sciences (GILD) plans to make more of its experimental remdesivir treatment available for Europe as of this coming autumn and will decide how much each country gets based on the rate of infection, Reuters writes. Bettina Bauer, managing director of Gilead in Germany, told WirtschaftsWoche that the company can increase its worldwide monthly production from currently 190,000 treatment cycles to 2 million treatment cycles in December. Bauer said she was in talks with the German government about increasing supply.

Continue to STAT Plus to read the full story…

Source link

Related posts

Appeals court backs Wright win in Spineology spat

Newsemia

Healing Justice and HIV

Newsemia

Medical devices for pain, other conditions have caused more than 80,000 deaths since 2008

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World